| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $69.0M | +10.9% | +8.4% |
| SG&A Expense | $14.4M | +7.4% | +21.7% |
| Operating Income | -$83.4M | -10.3% | -10.5% |
| Net Income | -$80.9M | -10.1% | -14.6% |
| EPS (Basic) | -$0.50 | +5.7% | +21.9% |
| EPS (Diluted) | -$0.50 | +5.7% | +21.9% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $125.3M | -1.8% | +29.1% |
| Current Assets | $397.2M | +62.1% | +16.3% |
| Total Assets | $425.9M | +55.0% | +10.9% |
| Current Liabilities | $62.2M | +6.5% | +17.3% |
| Long-term Debt | $44.3M | +0.7% | — |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$185.3M | — | — |
| Capital Expenditures | $743K | — | — |
| Investing Cash Flow | -$76.8M | — | — |
| Financing Cash Flow | $289.6M | — | — |
| Free Cash Flow | -$186.1M | — | — |
| $123.5M |
| +3.1% |
| +78.0% |
| Stockholders' Equity | $302.5M | +95.1% | -3.9% |